Advanced

Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma-a Nordic Lymphoma Group study.

Jerkeman, Mats LU ; Anderson, Harald LU ; Dictor, Michael LU ; Kvaløy, S.; Åkerman, Måns LU and Cavallin-Ståhl, Eva LU (2004) In Annals of Hematology 83(7). p.414-419
Abstract
The purpose of this study was to investigate the prognostic effects of four biological markers, BCL2, TP53, Ki-67, and P-glycoprotein, and their possible clinical relevance in addition to the international prognostic index (IPI) in diffuse large B-cell lymphoma (DLBCL). A total of 405 patients with aggressive lymphoma, stage II-IV, between 18 and 67 years, were randomized in a trial comparing CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) with MACOP-B (methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin). Of these, 267 cases were classified as DLBCL, with adequate paraffin blocks available in 207 cases, enabling immunohistochemical assessment of the expression of BCL2, TP53,... (More)
The purpose of this study was to investigate the prognostic effects of four biological markers, BCL2, TP53, Ki-67, and P-glycoprotein, and their possible clinical relevance in addition to the international prognostic index (IPI) in diffuse large B-cell lymphoma (DLBCL). A total of 405 patients with aggressive lymphoma, stage II-IV, between 18 and 67 years, were randomized in a trial comparing CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) with MACOP-B (methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin). Of these, 267 cases were classified as DLBCL, with adequate paraffin blocks available in 207 cases, enabling immunohistochemical assessment of the expression of BCL2, TP53, P-glycoprotein, and Ki-67. In a multivariate analysis, stratified for IPI, high BCL2 expression (>10%) low (<60%) expression of Ki-67, and high TP53 protein expression (>75%) were shown to provide additional prognostic information with regard to overall or failure-free survival. We found no association between expression of P-glycoprotein and outcome. Assessment of BCL2 positivity might be introduced as part of the routine investigation in patients with DLBCL, but further studies are necessary to confirm the clinical relevance of Ki-67 and TP53 expression. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
p-glycoprotein, diffuse large B-cell lymphoma, proliferation, TP53, BCL2
in
Annals of Hematology
volume
83
issue
7
pages
414 - 419
publisher
Springer Verlag
external identifiers
  • wos:000221733000002
  • pmid:15085385
  • scopus:3042776316
ISSN
1432-0584
DOI
10.1007/s00277-004-0855-x
language
English
LU publication?
yes
id
3f60a266-c424-47b6-b94e-4d6f4eeb6719 (old id 122662)
alternative location
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15085385&dopt=Abstract
date added to LUP
2007-07-19 08:22:46
date last changed
2017-08-06 03:38:10
@article{3f60a266-c424-47b6-b94e-4d6f4eeb6719,
  abstract     = {The purpose of this study was to investigate the prognostic effects of four biological markers, BCL2, TP53, Ki-67, and P-glycoprotein, and their possible clinical relevance in addition to the international prognostic index (IPI) in diffuse large B-cell lymphoma (DLBCL). A total of 405 patients with aggressive lymphoma, stage II-IV, between 18 and 67 years, were randomized in a trial comparing CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) with MACOP-B (methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin). Of these, 267 cases were classified as DLBCL, with adequate paraffin blocks available in 207 cases, enabling immunohistochemical assessment of the expression of BCL2, TP53, P-glycoprotein, and Ki-67. In a multivariate analysis, stratified for IPI, high BCL2 expression (&gt;10%) low (&lt;60%) expression of Ki-67, and high TP53 protein expression (&gt;75%) were shown to provide additional prognostic information with regard to overall or failure-free survival. We found no association between expression of P-glycoprotein and outcome. Assessment of BCL2 positivity might be introduced as part of the routine investigation in patients with DLBCL, but further studies are necessary to confirm the clinical relevance of Ki-67 and TP53 expression.},
  author       = {Jerkeman, Mats and Anderson, Harald and Dictor, Michael and Kvaløy, S. and Åkerman, Måns and Cavallin-Ståhl, Eva},
  issn         = {1432-0584},
  keyword      = {p-glycoprotein,diffuse large B-cell lymphoma,proliferation,TP53,BCL2},
  language     = {eng},
  number       = {7},
  pages        = {414--419},
  publisher    = {Springer Verlag},
  series       = {Annals of Hematology},
  title        = {Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma-a Nordic Lymphoma Group study.},
  url          = {http://dx.doi.org/10.1007/s00277-004-0855-x},
  volume       = {83},
  year         = {2004},
}